Eli Lilly and Company $LLY Stake Lessened by Pasadena Private Wealth LLC

Pasadena Private Wealth LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 65.5% during the 1st quarter, HoldingsChannel reports. The fund owned 942 shares of the company’s stock after selling 1,791 shares during the period. Pasadena Private Wealth LLC’s holdings in Eli Lilly and Company were worth $866,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Spire Wealth Management grew its position in shares of Eli Lilly and Company by 2.2% in the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after acquiring an additional 592 shares in the last quarter. Coldstream Capital Management Inc. raised its position in shares of Eli Lilly and Company by 25.6% during the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after acquiring an additional 8,659 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Eli Lilly and Company by 30.8% during the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock worth $33,471,000 after purchasing an additional 7,338 shares during the last quarter. Teachers Retirement System of The State of Kentucky lifted its stake in Eli Lilly and Company by 3.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock worth $126,022,000 after purchasing an additional 5,595 shares during the last quarter. Finally, Stonebridge Capital Advisors LLC boosted its holdings in Eli Lilly and Company by 318.1% in the third quarter. Stonebridge Capital Advisors LLC now owns 10,519 shares of the company’s stock worth $8,026,000 after purchasing an additional 8,003 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,226.22 on Tuesday. The company has a market cap of $1.15 trillion, a P/E ratio of 43.56, a PEG ratio of 1.32 and a beta of 0.53. The stock has a fifty day moving average price of $1,042.73 and a 200 day moving average price of $1,022.85. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,238.00.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period last year, the business posted $3.34 earnings per share. The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent research reports. Berenberg Bank boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Leerink Partners lifted their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday. Bank of America boosted their price objective on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,235.07.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA selected Eli Lilly for its new PreCheck pilot program, which is designed to speed review of new U.S. manufacturing facilities. That matters because Lilly is spending $27 billion to build four plants, so faster approvals could support capacity expansion and future drug supply. Article Title
• Positive Sentiment: Lilly’s Jaypirca received a positive opinion from Europe’s CHMP for chronic lymphocytic leukemia, improving the odds of broader European approval and potentially expanding the drug’s commercial opportunity. Article Title
• Positive Sentiment: The stock hit a new all-time high and 52-week high as investors reacted to recent pipeline progress, including positive Jaypirca data and expanded Medicare access for Zepbound and other obesity treatments, which boosts the outlook for Lilly’s growth franchises. Article Title

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.